These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 7859582)

  • 41. Twenty-four hour intragastric acidity during treatment with oral omeprazole.
    Pounder RE; Sharma BK; Walt RP
    Scand J Gastroenterol Suppl; 1986; 118():108-17. PubMed ID: 3460165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.
    Bell NJ; Hunt RH
    Gut; 1992 Jan; 33(1):118-24. PubMed ID: 1346769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of rabeprazole once daily for acid-related disorders.
    Lanza F; Bardhan KD; Perdomo C; Niecestro R; Barth J
    Dig Dis Sci; 2001 Mar; 46(3):587-96. PubMed ID: 11318537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease.
    Schentag JJ; Goss TF
    Am J Hosp Pharm; 1993 Apr; 50(4 Suppl 1):S7-10. PubMed ID: 8097364
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors.
    Lazzaroni M; Bianchi Porro G
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S73-8. PubMed ID: 10379473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.
    Fitton A; Wiseman L
    Drugs; 1996 Mar; 51(3):460-82. PubMed ID: 8882382
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer.
    Savarino V; Mela GS; Zentilin P; Bonifacino G; Moretti M; Valle F; Celle G
    Dig Dis Sci; 1989 Jul; 34(7):1043-6. PubMed ID: 2568246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 24-h recording of intragastric pH: technical aspects and clinical relevance.
    van Herwaarden MA; Samsom M; Smout AJ
    Scand J Gastroenterol Suppl; 1999; 230():9-16. PubMed ID: 10499456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Intragastric pH modifications induced by antisecretory treatments].
    Vallot T; Galmiche JP; Gouilloud-Celle S; Mignon M
    Gastroenterol Clin Biol; 1991; 15(5 ( Pt 2)):80C-87C. PubMed ID: 1680770
    [No Abstract]   [Full Text] [Related]  

  • 50. History of acid suppression: focus on the hospital setting.
    Garnett WR
    Pharmacotherapy; 2003 Oct; 23(10 Pt 2):56S-60S. PubMed ID: 14587958
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Acid-related pathology and prolonged continuous gastric pH monitoring. Physiopathologic findings and therapeutic implications].
    Celle G; Savarino V; Mela GS
    Recenti Prog Med; 1989 Sep; 80(9):485-92. PubMed ID: 2574489
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of intravenous and oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients.
    Cederberg C; Thomson AB; Mahachai V; Westin JA; Kirdeikis P; Fisher D; Zuk L; Marriage B
    Gastroenterology; 1992 Sep; 103(3):913-8. PubMed ID: 1499942
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Twenty-four-hour intragastric acidity and plasma gastrin concentration in healthy subjects and patients with duodenal or gastric ulcer, or pernicious anaemia.
    Lanzon-Miller S; Pounder RE; Hamilton MR; Chronos NA; Ball S; Mercieca JE; Olausson M; Cederberg C
    Aliment Pharmacol Ther; 1987 Jun; 1(3):225-37. PubMed ID: 2979225
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
    Törüner M; Bektaş M; Cetinkaya H; Soykan I; Ozden A
    Turk J Gastroenterol; 2004 Dec; 15(4):225-8. PubMed ID: 16249975
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
    Bardou M
    Rev Prat; 2001 Apr; 51(7):789-95. PubMed ID: 11387678
    [No Abstract]   [Full Text] [Related]  

  • 57. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity.
    Sharma BK; Walt RP; Pounder RE; Gomes MD; Wood EC; Logan LH
    Gut; 1984 Sep; 25(9):957-64. PubMed ID: 6469081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [In vivo evaluation of the effect of antacids and H2 receptor blockaders on the intragastric pH in gastric and duodenal ulcer].
    Waserstein M; Dacoll C; Cohen H; Gamboa L; Brener A; de Mizrahi JB; Sempol D; Neumark A; Nieto F; Tenzer S
    Acta Gastroenterol Latinoam; 1985; 15(4):243-55. PubMed ID: 2878555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sufotidine 600 mg bd virtually eliminates 24 hour intragastric acidity in duodenal ulcer subjects.
    Smith JT; Pounder RE
    Gut; 1990 Mar; 31(3):291-3. PubMed ID: 1969833
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Omeprazole in peptic ulceration: acid inhibition and endoscopic healing].
    Chen SP; Mai CR; Ke MY
    Zhonghua Nei Ke Za Zhi; 1989 Dec; 28(12):720-1, 767. PubMed ID: 2636088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.